111 citations
,
August 2015 in “Reviews in Endocrine and Metabolic Disorders” 5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.
March 2024 in “Journal of cosmetic dermatology” Isotretinoin can effectively reduce symptoms of frontal fibrosing alopecia.
24 citations
,
October 2008 in “International Braz J Urol” Lovastatin doesn't improve lower urinary tract symptoms treatment.
9 citations
,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
February 2016 in “PubMed” Properly administered testosterone therapy is safe and effective but often not covered by insurance.
42 citations
,
January 2019 in “Frontiers in Immunology” A blood pressure drug, diltiazem, may also help treat influenza.
6 citations
,
October 1993 in “Endocrinology” Finasteride blocks progesterone production in specific tumor cells, potentially causing side effects.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
April 2019 in “Journal of Investigative Dermatology” New vitamin D3 forms need the vitamin D receptor to reduce fibrosis in human cells.
10 citations
,
January 2015 in “The Journal of Clinical Pharmacology” No clear link between finasteride use and acute pancreatitis risk.
December 2024 in “PubMed” TrichoFoam™ effectively delivers multiple hair loss treatments, maintaining their stability and effectiveness.
17 citations
,
October 1980 in “PubMed” Valproic acid is effective for controlling seizures in children, especially as a single treatment, with some side effects.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
TrichoSolTM is safe for hair loss treatments with specific ingredient stability for up to 180 days.
February 2026 in “Revista Eletrônica Polidisciplinar Voos.” A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.
June 2017 in “Journal of The American Academy of Dermatology” Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.
68 citations
,
March 2018 in “Biomaterials” Tiny needles with valproic acid can effectively regrow hair.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
4 citations
,
August 2021 in “Annals of Translational Medicine” Dihydroartemisinin helps reduce prostate enlargement in rats by stopping the growth of prostate cells.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
October 2025 in “CRC Press eBooks” 3 citations
,
January 2018 in “Frontiers in bioscience” Daily subcutaneous testosterone effectively restores testosterone levels in men.
232 citations
,
June 1975 in “Journal of Steroid Biochemistry” Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.
5 citations
,
March 2016 in “Drug Development and Industrial Pharmacy” New drug delivery systems improve treatment effectiveness and patient experience.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
December 2020 in “American Journal of Transplantation” Early recognition and treatment of VATS in transplant patients improve outcomes.